



Target: caspase-1

in vitro:

VX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively. And VRT-043198 also inhibits IL-1 β release from both PBMCs and whole blood with IC50 of 0.67 μ M and 1.9 μ M, respectively.

in vivo:

In collagen-induced arthritis mouse model, VX-765 (200 mg/kg) inhibits LPS-induced IL-1 β production by about 60%, and results in a dose-dependent, statistically significant reduction in the inflammation scores and effective protection from joint changes. In vivo, VX-765 blocks kindling epileptogenesis in rats by preventing IL-1 β increase in forebrain astrocytes without significant effect on afterdischarge duration. In adult rats with genetic absence epilepsy (GAERS), VX-765, after the 3rd drug injection, significantly reduces the cumulative duration and number of spike-and-wave discharges (SWDs) by 55% on average by selectively blocking IL-1 β biosynthesis.

Note

- 1. Unless otherwise specified, the biochemical reagents produced by our company are generally non-sterile packaged. If they are to be used for cell experiments, please conduct pretreatment in advance.
- 2. Once dissolved, please store the solution in separate containers to avoid product degradation caused by repeated freezing and thawing.
- 3. The product information is for reference only. If you have any questions, please call 400-968-6088 for consultation.
- 4. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
- 5. For your safety and health, please wear laboratory clothes, disposable gloves and masks to operate.